Lipopolyamines as a therapeutic strategy in experimental Gram-negative bacterial sepsis

Journal of Endotoxin Research

Volumn 7, Issue 1, 2001, Pages 35-38

  Opal, Steven M ^a   Palardy, John E ^a   Parejo, Nicolas ^a   Morrison, David C ^b  

^a BROWN UNIVERSITY   (United States)

^b Saint Luke's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DI OLEOYLOXY 2 (6 CARBOXYLSPERMYL)PROPYLAMIDE; AMIDE; AMINE; ANTIBIOTIC AGENT; ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; CEFAMANDOLE; CEFTAZIDIME; CYCLOPHOSPHAMIDE; CYTOKINE; DEXTRAN; INTERLEUKIN 6; LIPID A; LIPOPOLYAMINE; LYMPHOCYTE ANTIBODY; POLYMYXIN B; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BINDING AFFINITY; BLOOD LEVEL; CIRCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; GRAM NEGATIVE SEPSIS; LETHALITY; LIVER; MACROMOLECULE; MODEL; MORTALITY; NEUTROPENIA; NONHUMAN; PROVOCATION TEST; PSEUDOMONAS AERUGINOSA; RAT; SPLEEN; SURVIVAL;

ANIMALS; BACTEREMIA; CEFTAZIDIME; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; GRAM-NEGATIVE BACTERIAL INFECTIONS; NEUTROPENIA; RATS; SEPSIS; SURVIVAL ANALYSIS;

ANIMALIA; BACTERIA (MICROORGANISMS); NEGIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0034982110     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805101101532503     Document Type: Article

References (15)

1. The clinical significance of quantitative measurement of plasma endotoxin and LPS-binding protein in severe sepsis
2. Pathogenic mechanisms of septic shock
3. Consensus conference definitions of sepsis, acute lung injury and ARDS-time for re-evaluation
4. Bacterial endotoxin: Molecular relationships of structure to activity and function
5. Anti-endotoxin strategies for the prevention and treatment of septic shock
6. Lipopolyamines: Novel antiendotoxin compounds that reduce mortality in experimental sepsis by Gram-negative bacteria
7. Potential hazards of combination immunotherapy in the treatment of experimental sepsis
8. Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of Gram-negative sepsis
9. Circulating endotoxin during initial antibiotic treatment for severe Gram-negative bacteremic infections
10. The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against Gram-negative bacteria and lipopolysaccharide
11. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides
12. Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA
13. Interaction of cationic amphiphilic drugs with lipid A: Implications for development of endotoxin antagonists
14. Cationic liposome-mediated gene transfer
15. Immunotherapy of malignancy by in vivo gene transfer therapy